TY - JOUR
T1 - General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation
AU - Saliba, Rima M.
AU - Rezvani, Katayoun
AU - Leen, Ann
AU - Jorgensen, Jeffrey
AU - Shah, Nina
AU - Hosing, Chitra
AU - Parmar, Simrit
AU - Oran, Betul
AU - Olson, Amanda
AU - Rondon, Gabriela
AU - Chen, Julianne
AU - Martinez, Charles
AU - Hamdi, Amir
AU - Mehta, Rohtesh S.
AU - Chemaly, Roy F.
AU - Saunders, Ila M.
AU - Bollard, Catherine M.
AU - Shpall, Elizabeth J.
N1 - Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Cord blood transplantation (CBT) is curative for many patients with hematologic malignancies but is associated with delayed immune recovery and an increased risk of viral infections compared with HLA-matched bone marrow or peripheral blood progenitor cell transplantation. In this study we evaluated the significance of lymphocyte recovery in 125 consecutive patients with hematologic malignancies who underwent double-unit CBT (DUCBT) with an antithymocyte globulin-containing regimen at our institution. A subset of 65 patients was prospectively evaluated for recovery of T, natural killer (NK), and B cells, and in 46 patients we also examined viral-specific T cell recovery against adenovirus, Epstein-Barr virus, cytomegalovirus, BK virus, respiratory syncytial virus, and influenza antigen. Our results indicate that in recipients of DUCBT, the day 30 absolute lymphocyte count is highly predictive of nonrelapse mortality and overall survival. Immune recovery post-DUCBT was characterized by prolonged CD8+ and CD4+ T lymphopenia associated with preferential expansion of B and NK cells. We also observed profound delays in quantitative and functional recovery of viral-specific CD4+ and CD8+ T cell responses for the first year post-CBT. Taken together, our data support efforts aimed at optimizing viral-specific T cell recovery to improve outcomes post-CBT.
AB - Cord blood transplantation (CBT) is curative for many patients with hematologic malignancies but is associated with delayed immune recovery and an increased risk of viral infections compared with HLA-matched bone marrow or peripheral blood progenitor cell transplantation. In this study we evaluated the significance of lymphocyte recovery in 125 consecutive patients with hematologic malignancies who underwent double-unit CBT (DUCBT) with an antithymocyte globulin-containing regimen at our institution. A subset of 65 patients was prospectively evaluated for recovery of T, natural killer (NK), and B cells, and in 46 patients we also examined viral-specific T cell recovery against adenovirus, Epstein-Barr virus, cytomegalovirus, BK virus, respiratory syncytial virus, and influenza antigen. Our results indicate that in recipients of DUCBT, the day 30 absolute lymphocyte count is highly predictive of nonrelapse mortality and overall survival. Immune recovery post-DUCBT was characterized by prolonged CD8+ and CD4+ T lymphopenia associated with preferential expansion of B and NK cells. We also observed profound delays in quantitative and functional recovery of viral-specific CD4+ and CD8+ T cell responses for the first year post-CBT. Taken together, our data support efforts aimed at optimizing viral-specific T cell recovery to improve outcomes post-CBT.
KW - Absolute lymphocyte count
KW - B cells
KW - NK cells
KW - Post-transplant
KW - Post-transplant infections
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=84929005503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929005503&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2015.02.017
DO - 10.1016/j.bbmt.2015.02.017
M3 - Article
C2 - 25708219
AN - SCOPUS:84929005503
SN - 1083-8791
VL - 21
SP - 1284
EP - 1290
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 7
ER -
